All In Biotech

Drug Trial Radar · NCT07147348

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Aug 27, 2025

Primary completion

Nov 2027

Study completion Aug 2028

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Biotheus (Hengqin) Co., Ltd.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
First posted
Aug 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

Conditions

  • Advanced Solid Tumor

Interventions

  • BNT3212Biological

    Intravenous infusion

  • PumitamigBiological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and C - Occurrence of dose limiting toxicities (DLTs) within a participant during the DLT observation periodTime frame: Up to 28 days after first dose of investigational medicinal product (IMP).
  2. All parts - Percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs by relationshipTime frame: From the time of the first dose of IMP until 90 days after the last dose of IMP, approximately up to 31 months.
  3. Parts A and C - Percentage of participants with dose interruptions or discontinuations of study treatment due to TEAEsTime frame: From the time of the first until last dose of IMP, approximately up to 31 months.
  4. Parts B and D - Percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEsTime frame: From the time of the first until last dose of IMP, approximately up to 31 months.
  5. Parts B and D (expansion cohorts) - Objective response rate (ORR)Time frame: From first dose of IMP until end of study, approximately up to 31 months.

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Research SA

    Adelaide, Australia · Recruiting

  • Monash Medical Centre

    Clayton, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Australia · Recruiting

  • One Clinical Research

    Nedlands, Australia · Not yet recruiting

  • Scientia Clinical Research Limited

    Randwick, Australia · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, China · Recruiting

  • First Affiliated Hospital of Xinxiang Medical University

    Henan, China · Recruiting

  • Hunan Province Cancer Hospital

    Hunan, China · Not yet recruiting

  • Shandong University-Jinan Central Hospital

    Shandong, China · Recruiting

  • Qilu Hospital of Shandong University'

    Shandong, China · Not yet recruiting

  • Linyi Tumor Hospital

    Shandong, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Shanghai GoBroad Cancer Hospital

    Shanghai, China · Recruiting

  • Sichuan Cancer Hospital

    Sichuan, China · Recruiting

  • Zhejiang Cancer Hospital

    Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.